Phase 4 N=40 Comparison of Excision Versus Punch Incision in the Treatment of Epidermal Cysts
Epidermal Cyst
Primary: Number of Participants With Cyst Recurrence — 3; 2 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=33 Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms
Neoplasms, Cystic, Mucinous, and Serous
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 7; 16 participants
Phase 4 N=100 Interest in the Use of Dressings With Honey for Wound Healing After Excision of Pilonidal Cyst
Pilonidal Cysts
Primary: Healing Time — 78; 61 Days — p=0.094
N/A N=30 CellFX Treat & Resect Low-Risk BCC Feasibility Study
BCC - Basal Cell Carcinoma · BCC · Excision Margin
Primary: Number of Lesions With BCC Histological Clearance — 34 BCC Lesions
N/A N=66 In Vivo nCLE Study in the Pancreas With Endosonography of Cystic Tumors
Pancreatic Cysts
Primary: Sensitivity — 59 percentage of participants
N/A N=150 Chalazion Conservative Treatment Trial
Chalazion Unspecified Eye, Unspecified Eyelid · Chalazion Left Eye, Unspecified Eyelid · Chalazion Right Eye, Unspecified Eyelid
Primary: Number of Participants With Complete Resolution — 13; 12; 11 participants
Phase 2 N=2 A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors
Keratocystic Odontogenic Tumor
Primary: KCOT Volume (Greatest Dimension) — 3; 3.8; 0; 2.6 centimeter
Phase 2 N=20 Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms
Pancreatic Mucinous-Cystic Neoplasm
Primary: Number of Participants With Treatment Emergent Adverse Events (Safety and Tolerability) — 3; 3; 3; 9 Participants
N/A N=124 CellFX System for the Treatment of Cutaneous Non-Genital Warts
Warts · Warts Hand · Verruca
Primary: Percentage of Verrucae Cleared — 67.6 percentage of verrucae clearance
Phase 2 N=186 Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
Superficial Basal Cell Carcinoma
Primary: Number of Participants With Complete Response — 9; 5; 7; 9 Participants
Phase 2 N=8 Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
Epidermolysis Bullosa Simplex · Epidermolysis Bullosa Simplex Kobner · Weber-Cockayne Syndrome
Primary: Foot Health Status Questionnaire, Foot Function Domain Score — 61.7; 49.3; 60.2; 56.3 score on a scale
Phase 2 N=10 Histopathology Following CCH Injection
Characteristics of Subcutaneous Tissue
Primary: Number of Participants With a Histologic Change in a Tissue Specimen That Was Injected With CCH — 2; 1; 1; 2 Participants
N/A N=33 Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma
Basal Cell Carcinoma
Primary: This is a Study to Measure the Efficacy of the Nd:YAG Laser to Cause Complete Regression of Basal Cell Carcinoma. — 28 tumors
Phase 2 N=94 Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Basal Cell Carcinoma · Skin Cancer · Cancer of the Skin, Basal Cell
Primary: Part 1: Percentage of Subjects With Discontinuations Due to Adverse Events — 0 Participants
N/A N=32 Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors
Skin Rash
Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…